BBC News World

The remains discovered in the national forest of New Mexico are identified as Melissa Casias’s

Authorities said that human remains found last week by a hiker in a New Mexico forest were those of an employee of Los Alamos National Laboratory who has been missing since nearly a year. Subscribe to this story to enjoy it ad free

Casias family representatives said they will not make any comments until the next meeting with investigators. Los Alamos National Laboratory representatives did not immediately respond to an inquiry for comment on Sunday. Casias was walking on a highway about six miles away from her home when she was reported as missing. Casias was reported missing by her supervisor on June 26 after she failed to report for work. Her husband Mark Casias said this in an interview. Melissa Casias went missing in June. Authorities confirmed that Thursday, her remains had been found in the New Mexico National Forest. Mark Casias reported that his wife dropped him at the federal energy research institute where they both worked earlier in the day. He claimed that Casias had told him that she was going somewhere else in the lab to finish a task, but she did not return. Sierra, the couple’s daughter said that she found later her mother’s belongings in Ranchos de Taos in their home, including keys and an old cellphone with factory settings. A family friend also saw Melissa walking on State Road 518 that afternoon. State Police Sergeant. Ricardo Breceda told us last year. Mark then said that he reviewed documents which showed Melissa to be under a lot of stress. He declined to give any further details. Breceda stated last year that Casias “may have” dispeared on her own accord, even though the police had not ruled out foul play. In their statement, the State Police extended their “deepest sympathy” to Casias and her family. They stated that the investigation continues. Melissa Casias

BBC News World

Colombian Petro casts doubt on election that shows his favorite successor headed for runoff against Trump-supporting rival

Colombian outgoing President Petro cast doubt on Sunday regarding the country’s elections. His preferred candidate, Ivan Cepeda was heading to a next-month runoff against his right-wing opposition Abelardo de la Espriella. Subscribe to this story and read it ad free

Cepeda stated in a Bogota speech that “today we have secured 10,000,000 votes which were incorrectly counted in Colombia.” “There is an anomaly that we would like to verify.” Hernan Pennagos is the head of the office. He said

the preliminary count for this year’s congress elections was 99.8% precise – a historical high compared with final results. Human Rights Watch’s Americas Director Juanita Goebertus said

Colombia’s electoral system is “independent and trustworthy.”

De la Espriella will advance to the second round. She called on the international community, urging them to support the National Civil Registry. Sunday’s election results set the stage of a showdown that will pit Cepeda – a leftist senator who negotiated Colombia’s historic peace deal in 2016 – against de la Espriella – a lawyer, political outsider, who has declared himself an ally of U.S. president Donald Trump, and who has promised to crackdown crime. De la Espriella said, “We will defeat absolute tyranny,” after it was clear that he would be advancing to the runoff in June. Abelardo de la Espriella of the Defensores de la Patria has positioned himself to be an outsider, eager to mimic the heavy-handed tactic used by El Salvador in its war on gangs. Vanessa Romero / – via Paloma Valencia, a conservative Centro Democratico Party candidate, and former protegee of the right-wing former Colombian president Alvaro Uribe who pitched herself as an able centrist, was predicted to make it through to the second stage. She received less than 7% votes on Sunday, which knocked her out of contention.

Valencia voters, who opposed the left-wing mandate of Petro for a term limited, could support de la Espriella during the next round to decide the new leader. Valencia announced its support for de la Espriella during a Sunday news conference following the results. Sunday’s election is seen as an assessment of Petro’s policy. This comes ten years after Colombia signed the historic peace treaty with the Revolutionary Armed Forces of Colombia or FARC. This agreement gave Colombians hope that the country could break its vicious cycle between rebel groups, the government and the armed forces. But violence has returned since then. It reached a climax in the run-up to Sunday’s presidential election. The race has been plagued by armed attacks and drone strikes from criminal groups. Last June, presidential candidate Miguel Uribe Turbay was shot dead at a rally. Petro, the first leftist President of the modern age and a former Marxist revolutionary, has been at odds with Trump on many occasions. He used these disputes to boost his reputation. The two leaders had a private meeting in the Oval Office on February 10, and Petro was given a baseball c with the words “Make America Great Again.” Trump signed a copy of his book, “The Art of the Deal,” and left the White House. Trump later said that he and Petro got along well. Some U.S. officials, however, have taken steps to highlight de la Espriella’s candidacy and suggest that voting for Cepeda would be a mistake. A polling station in Medellin Saturday. Camilo Moreno/ NurPhoto – via . Camilo Moreno/ NurPhoto – via .

At an Atlantic Council event last week, Sen. Bernie Moreno (R-Ohio), who is advising Trump on his policy towards Colombia, and who was present at Petro and Trump’s February meeting, stated that Colombia’s upcoming elections will be crucial and determine “where people are going decide which way they want to go.” Moreno announced that he will be the international observer of this week’s elections to ensure a safe and free election. Petro responded to Moreno’s words

, asking him to not make comments “different” from those that pertain to his mission as an electoral overseer. said in March Political statements regarding the citizenry’s vote are illegal interferences in the free decisions of the people,” Petro declared. Other U.S. legislators also weighed in before the election. Rep. Maria Elvira Salazar (R-Fla.), officially endorsed de la Espriella before the election. Moreno and others, including R. Florida legislator

have congratulated de la Espriella after the results were announced. said Sunday on X “Democracy has won today, but there is still work to be done.” Moreno said

that a runoff will take place in three weeks. “I’ll be there to watch the final rounds at the CNE request,” Moreno said.

BBC News World

The doctors are looking at other uses for the new drug

After the ‘unprecedented” results of the pancreatic pancreatic cancer cancer drug, they look to other uses

Enjoy unlimited access to exclusive articles and ad-free content. Wainberg, the co-director of UCLA Health’s GI Oncology Program was leading a trial of a drug called daraxonrasib. All participants in the study had received chemothery before, but it was failing. Wainberg: “Statistically I knew only half would receive the pill. We don’t even get to pick.” “I’ve put many patients on chemo, and they’re all dead now.”

The excitement surrounding

continues to grow. In a phase three trial involving 500 patients, the drug showed to double the time patients survived with advanced pancreatic, a cancer that is notoriously fatal: 13.2 month, on average. This was compared to the 6.7 month survival for patients who had chemo. Wainberg and colleagues presented the results of their study at the American Society of Clinical Oncology’s annual meeting, which took place in Chicago on Sunday. The complete study was published simultaneously in the

Enthusiasm around daraxonrasib. When Revolution Medicines released the New England Journal of Medicine.

of the trial in ril, Rachna Schroff, chief of division of hematology, and oncology, at the University of Arizona Cancer Center, in Tucson, “started to cry tears of joy”. It’s unprecedented. preliminary findings The excitement has spread to other cancer types. Daxaronrasib is a three-pill daily treatment that targets a mutation of the KRAS gene, found in many types of cancer, including lung, colorectal and endometrial, as well as

. Daraxonrasib research was led by Dr. Brian Wolpin at the Hale Family Center for Pancreatic Cancer Research of Dana-Farber Cancer Institute. Patrick Martin / NBC News “Now, the floodgates are open.”

According to the Food and Drug Administration, the drug is already on a fast-track to proval for pancreatic carcinoma. Earlier this month the FDA said that Revolution Medicines could give the drug to patients outside clinical trials. bile duct cancer called cholangiocarcinoma The chief executive of Revolution Medicines, Dr. Mark Goldsmith declined to say when the company would file for FDA clearance. He said that “our professionals work literally 24 hours a day to prepare this material as quickly as we can.” The shrinking tumor

Pancreatic cancer is usually diagnosed at a later stage of the disease when surgery is not an option. Dr. Sameek Roychowdhury is a medical oncologist and gastrointestinal specialist at the Ohio State University Comprehensive Cancer Center. He said that even with the best of chemotheries the average benefit can be as short as six months. According to the , only 3% of those diagnosed with metastatic cancer pancreatic are still alive after five years. Debby Orcutt (71), was diagnosed in ril of 2024 with stage 4 pancreatic carcinoma. The cancer had spread to her liver. Before her diagnosis, the only thing she had experienced was a persistent pain in her lower left abdominal area that got worse during the night. Orcutt enrolled in a clinical trial of daraxonrasib when chemothery failed. She was one participant who received the drug.

The spot on Orcutt’s liver dispeared since she started taking the pill, in January 2025. According to her oncologist, the tumor in her pancreas shrank by 80%. Orcutt of Spencer, Massachusetts, said, “I feel fantastic every day.” “I don’t dwell on the fact I have pancreatic carcinoma.”

Although neither Roychowdhury or Shroff was involved in clinical trials, they have both already started curating a patient list to receive the drug when it becomes available. Shroff stated that he would start taking the drug as soon as it became available. What is daraxonrasib, and how does it function? Daraxonrasib works by targeting a mutation within a KRAS gene, which acts as an on/off switch that controls how cells grow. The mutation found in pancreatic cancers causes the switch to remain in the “on” position. This allows cancerous cells to grow uncontrollably. Scientists knew for years that they could remove the switch from “on” if they targeted the KRAS mutation. Wolpin explained that “it’s been extremely hard to drug this mutation.” The mutated protein looks like a ball and it’s impossible to get a drug to adhere to it or block its effect. Daraxonrasib, expanded access program is the first drug. It pairs up with a cyclophilin A protein inside cells and acts like a “molecular adhesive,” Wolpin explained, glomming on the mutated proteins.

There are studies underway for similar drugs. Daraxonrasib, while not a cancer cure, can help tumors to find new ways to grow. Oncologists should have an arsenal of drugs similar to this one ready to use when patients develop resistance. Goldsmith of Revolution Medicine said that three RAS-inhibitors, also known as similar drugs, are currently in clinical trial, and a fourth is due to begin later this summer. Daraxonrasib pears to be effective beyond the KRAS mutation. The overall survival for all patients receiving the drug was 13.2 month, regardless of the KRAS gene mutation. Wolpin: “Based on what we know now, I’m confident that this drug will be effective for all patients with metastatic pancreatic carcinoma, provided they also have metastatic cancer.” This is a step in the right direction to stop relying on so much chemothery. Wolpin stated that further research is ongoing to determine whether these patients should receive the drug first.

Daraxonrasib pears to be less toxic than chemo. Some patients complained of vomiting, diarrhea, and sores around the mouth and throat. Some patients developed blistering rashes that looked like bad sunburns. Ben Sasse described his rash on

, which he received as part of a trial, as “nuclear”. Debby Orcutt, who received daraxonrasib in a clinical trial, said that her side effects were minimal. She had a small rash on her hand and what she described as a large canker sore. “We are talking about life and death,” she said. “How could I complain about such a tiny rash?” Debby Orcutt, and her husband Ron Orcutt. Debby Orcutt –

Orcutt –

Orcutt & her husband Ron Orcutt of 47 years met as teenagers working part time at a mall. She worked as a shoe salesperson at Thom McAn, and he was a department store employee at Zayre. She was 17, he was 18 They still giggle together like two school children. Ron Orcutt is the one who carefully records his wife’s daraxonrasib doses. He ensures that his wife takes the pills exactly at the correct time, setting alarms when necessary. They must be taken with an empty stomach. This is exactly two hours after husband and wife had breakfast together. American Cancer Society These reminders are needed. Debby Orcutt will be out the door by then, helping her granddaughters get to school in time, or heading to her new part-time work wiping down tables at a local high school. It keeps her active, though she does not need to work. “You just have to keep moving and have faith.” “Everyone has to live everyday as if it is their last,” said she. “I feel as if I have been given a chance to make the most out of it.”

BBC News World

Trump Visit 01 official in Ebola epicenter as deadly outbreak spreads

01:44

A.I. There The The official in Ebola epicenter as deadly outbreak spreads

01:44

A.I. A

Continue Reading

BBC News World

Due Please The official in Ebola epicenter as deadly outbreak spreads

01:44

A.I. The NBC News’ Valerie Castro reports. Good official in Ebola epicenter as deadly outbreak spreads

01:44
A.I. A

Continue Reading

BBC News World

Subscribe to read the story without ads

Receive unlimited access to adfree articles and exclusive material. Oil prices are up in January 2010 amid reports that Trump and Iran may be nearing an agreement. The two sides have been unable to reach a deal for more than a month. Although U.S. officials and Arab officials have indicated for days that the agreement is close to finalization, neither side has proved it. Marco Rubio, the Secretary of State, had said that there would be “good news,” within hours. But Trump, who said that Iran must agree not to have nuclear weons, demanded that the Strait of Hormuz is reopened to “unrestricted traffic in both directions” and that all final determination be “destroyed” in a statement on Friday, refused to make any further statements. The deal is expected to prolong the current ceasefire, which has been in effect since early ril. Both sides have accused each other of violating the agreement with their continued strikes. U.S. officials confirmed Friday that the White House is reviewing a deal to begin 60 days of talks with Iran regarding its nuclear program. However, neither side has proved the agreement. Iran has painted an entirely different picture of the agreement than the White House and called U.S. requirements “excessive.” “He has proved that he’s not a person who negotiates and is pursuing his other objectives by continuing the blockade of the navy and making excessive demands in negotiations,” said Rezaei. Iran war agreement needs Trump’s proval, Iranian leaders say. The official described the delays as frustrating. “It had already been closed in Doha, three days ago. Now everyone is playing the game of chicken and the egg,” he said.